Brief: Inhibikase Therapeutics Announces Advancement Of Ikt-148009 Phase 2 '201' Program Following FDA Review
13/06/2022 13:14
June 13 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES ADVANCEMENT OF
IKT-148009
PHASE 2 '201' PROGRAM FOLLOWING FDA REVIEW
* INHIBIKASE THERAPEUTICS INC- PHASE 1/1B '101' STUDY
TERMINATED
EARLY; DEMONSTRATED FAVORABLE SAFETY, TOLERABILITY
* INHIBIKASE THERAPEUTICS INC- PHASE 2A '201' STUDY OPEN FOR
ENROLLMENT; EXPECT TO DOSE FIRST PATIENT IN 2Q 2022
* INHIBIKASE THERAPEUTICS INC - PHASE 1/1B '101' STUDY
TERMINATED
EARLY
Source text for Eikon: ID:nPn77Zsxga
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share